Venus Remedies Q1 Results FY27: Net Profit Jumps 139.27% to Rs 22 Cr as Revenue Grows 35.6%
- July 21, 2026
- Posted by: Kunal Singla
- Category: News
Venus Remedies Q1 FY27: PAT Rs 22 Cr (+139.27% YoY), revenue Rs 178 Cr (+35.6%). Stock fell 4.30% to Rs 1,693.90 on 20 July 2026.
Venus Remedies Q1 results FY27, announced on Monday, 20 July 2026, show a consolidated net profit of Rs 22 Cr for the quarter ended 30 June 2026, up 139.27% from Rs 9 Cr in the year ago quarter.
Shares of Venus Remedies fell 4.30% to Rs 1,693.90 on the results day. The company is a research driven pharmaceutical company focused on critical care injectables.
Click Here – Get Free Investment Predictions
Venus Remedies Q1 Results FY27 Key Takeaways
Here are the most important numbers from the June 2026 quarter at a glance.
- Net Profit (PAT): Rs 22 Cr in Q1 FY27 versus Rs 9 Cr in Q1 FY26, a change of +139.27% year on year.
- Revenue: Rs 178 Cr in Q1 FY27 versus Rs 131 Cr in Q1 FY26, a change of +35.6%.
- Gross Profit: Rs 27 Cr in Q1 FY27 versus Rs 3 Cr in Q1 FY26, a change of +599.49%.
- Results announced on Monday, 20 July 2026 for the quarter ended 30 June 2026 on a consolidated basis.
- Venus Remedies share price fell 4.30% to Rs 1,693.90 on the results day.
Venus Remedies Q1 Results FY27 Financial Highlights
The table below summarises the consolidated numbers reported in the Venus Remedies Q1 results FY27 against the year ago quarter.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 178 Cr | Rs 131 Cr | +35.6% |
| Gross Profit | Rs 27 Cr | Rs 3 Cr | +599.49% |
| Net Profit (PAT) | Rs 22 Cr | Rs 9 Cr | +139.27% |
All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.
Venus Remedies Q1 Results FY27 Performance Analysis
Get Personalised Guidance from a SEBI-Registered Investment Advisor
Profit growth is the headline of the Venus Remedies Q1 results FY27. Revenue grew 35.6% to Rs 178 Cr from Rs 131 Cr. Gross profit rose 599.49% to Rs 27 Cr from Rs 3 Cr.
Gross profit growing faster than revenue shows operating leverage at work in the Venus Remedies Q1 results FY27, with margins expanding as scale builds.
Venus Remedies Q1 Results FY27: Key Business Factors
1. Topline Momentum
Revenue grew 35.6% to Rs 178 Cr from Rs 131 Cr. This sets the base against which the rest of the P&L in the Venus Remedies Q1 results FY27 should be read.
2. Operating Performance
Gross profit rose 599.49% to Rs 27 Cr from Rs 3 Cr. The gross profit trend is the cleanest read on operating health in the quarter.
3. Bottom Line Delivery
The net result of Rs 22 Cr captures the combined effect of operations, other income, finance costs and tax for the quarter.
Dividend Details
Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company’s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.
Venus Remedies Q1 Results FY27 Outlook for the Full Year
Looking past the Venus Remedies Q1 results FY27, the FY27 trajectory depends on demand conditions in the company’s core markets, cost trends, and execution against the base this quarter has set.
Venus Remedies Stock Performance After the Q1 Results
Download the Univest iOS App or Univest Android App to track Venus Remedies live share price and upcoming quarterly results.
Venus Remedies share price fell 4.30% to Rs 1,693.90 on the results day, as the market weighed the quarter’s numbers against expectations.
Investors can compare the trend of the counter with the Nifty 500 index to judge how the stock is placed relative to the broader market after the June quarter results.
Key Risks
Investors going through the fine print of the Venus Remedies Q1 results FY27 should also weigh the following risks.
1. Sustaining the Growth Rate
The growth reported in the Venus Remedies Q1 results FY27 sets a higher base for coming quarters, and any moderation could disappoint a market that extrapolates.
2. Margin Durability
Whether the quarter’s operating performance holds depends on input costs, pricing power and mix, all of which can shift quickly.
3. Execution and External Risks
Demand cycles, regulatory changes and sector specific shocks remain outside management control and can reset expectations.
Conclusion
Venus Remedies Q1 results FY27 show consolidated net profit of Rs 22 Cr for the quarter ended 30 June 2026, up 139.27% from Rs 9 Cr in the year ago quarter. Revenue grew 35.6% to Rs 178 Cr from Rs 131 Cr. The September quarter will show whether this quarter’s trend extends. Investors should verify the filings on NSE and BSE and consult a SEBI-registered advisor before acting on the numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Venus Remedies Q1 Results FY27
When were the Venus Remedies Q1 results FY27 announced?
Ans. The Venus Remedies Q1 results FY27 were announced on Monday, 20 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.
What is the PAT in the Venus Remedies Q1 results FY27?
Ans. The consolidated PAT in the Venus Remedies Q1 results FY27 stood at Rs 22 Cr, a change of +139.27% from Rs 9 Cr in Q1 FY26.
What was the revenue in the Venus Remedies Q1 results FY27?
Ans. The revenue in the Venus Remedies Q1 results FY27 stood at Rs 178 Cr, a change of +35.6% from Rs 131 Cr in Q1 FY26.
What was the gross profit in the Venus Remedies Q1 results FY27?
Ans. Gross profit for the June 2026 quarter stood at Rs 27 Cr, compared with Rs 3 Cr in Q1 FY26, a change of +599.49% year on year.
Are the Venus Remedies Q1 results FY27 standalone or consolidated?
Ans. The figures discussed here are on a consolidated basis, as reported for the quarter ended 30 June 2026.
How did the share price react after the Venus Remedies Q1 results FY27?
Ans. Venus Remedies share price fell 4.30% to Rs 1,693.90 on the results day.
Is the stock a good buy after the Venus Remedies Q1 results FY27?
Ans. The Venus Remedies Q1 results FY27 are one input among many. Valuation, sector conditions and risk appetite matter as much as a single quarter. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.
Where can I verify the Venus Remedies Q1 results FY27?
Ans. The official filings for the Venus Remedies Q1 results FY27 are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.
